After a corona infection, children usually have only mild symptoms or no symptoms at all, but they can still carry the virus.
The US company Moderna is starting a series of tests on children under twelve and examining the effectiveness and tolerability of its corona vaccine.
A total of around 6750 healthy children between the ages of six months and 11 years should take part. The clinical tests in the USA and Canada have already started, Moderna announced on Tuesday. For this purpose, in the so-called phase 2/3 study, they would initially be given two smaller doses of the mRNA active ingredient successfully tested in adults at intervals of 28 days.
Moderna boss Stéphane Bancel (48) said the study would help to better assess the safety and effectiveness of the vaccine mRNa-1273 for the very important child population.
Since infections with Sars-CoV-2 often go unnoticed in young children, but they can infect other people, daycare centers and schools are closed again and again all over the world to contain the pandemic.
Like the Mainz-based company Biontech, Moderna has developed a corona vaccine based on the new mRNA technology, of which two doses are required for immunization against the novel coronavirus.
The Moderna vaccine has been approved for adults in the EU since January 6th. In the USA, an emergency license was granted back in December. Vaccinating children under the age of 16 with the corona vaccines previously approved in the United States is not allowed.